sST2 Levels Show No Association with Helicobacter pylori Infection in Asymptomatic Patients: Implications for Biomarker Research.
Biomarker
Cancer
H. pylori
Soluble suppression of tumorigenicity-2
sST2
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
28
03
2023
accepted:
13
06
2023
medline:
19
7
2023
pubmed:
20
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
Helicobacter pylori (H. pylori) is a prevalent stomach bacterium that can cause a range of clinical outcomes, including gastric cancer. In recent years, soluble suppression of tumorigenicity-2 (sST2) has gained attention as a biomarker associated with various diseases, such as gastric cancer. The purpose of this study was to explore the possible connection between H. pylori infection and sST2 levels in patients who do not exhibit symptoms. A total of 694 patients from the Salzburg Colon Cancer Prevention Initiative (Sakkopi) were included in the study. The prevalence of H. pylori infection was determined by histology, and sST2 levels were measured in serum samples. Clinical and laboratory parameters, such as age, sex, BMI, smoking status, hypertension, and metabolic syndrome, were also collected. The median sST2 concentration was similar between patients with (9.62; 7.18-13.44 ng/mL; p = 0.66) and without (9.67; 7.08-13.06 ng/mL) H. pylori. Logistic regression analysis did not show any association (OR 1.00; 95%CI 0.97-1.04; p = 0.93) between sST2 levels and H. pylori infection, which remained so (aOR 0.99; 95%CI 0.95-1.03; p = 0.60) after adjustment for age, sex, educational status, and metabolic syndrome. In addition, sensitivity analyses stratified by age, sex, BMI, smoking status, educational status, and the concomitant diagnosis of metabolic syndrome could not show any association between sST2 levels and H. pylori infection. The results indicate that sST2 may not serve as a valuable biomarker in the diagnosis and treatment of H. pylori infection. Our findings are of relevance for further research investigating sST2, as we could not find an influence of asymptomatic H. pylori infection on sST2 concentration. WHAT IS ALREADY KNOWN?: Soluble suppression of tumorigenicity-2 (sST2) has gained attention as a biomarker associated with various diseases, such as gastric cancer. WHAT IS NEW IN THIS STUDY?: The median sST2 concentration was similar between patients with (9.62; 7.18-13.44 ng/mL; p = 0.66) and without (9.67; 7.08-13.06 ng/mL) H. pylori. WHAT ARE THE FUTURE CLINICAL AND RESEARCH IMPLICATIONS OF THE STUDY FINDINGS?: The results indicate that sST2 may not serve as a valuable biomarker in the diagnosis and treatment of H. pylori infection.
Identifiants
pubmed: 37338618
doi: 10.1007/s10620-023-08005-0
pii: 10.1007/s10620-023-08005-0
pmc: PMC10352442
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3293-3299Informations de copyright
© 2023. The Author(s).
Références
Chey WD, Leontiadis GI, Howden CW et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212–239.
doi: 10.1038/ajg.2016.563
pubmed: 28071659
Braden B. Diagnosis of Helicobacter pylori infection. BMJ 2012;344:e828.
doi: 10.1136/bmj.e828
pubmed: 22368293
Kavitt RT, Cifu AS. Management of Helicobacter pylori infection. JAMA 2017;317:1572–1573.
doi: 10.1001/jama.2017.1949
pubmed: 28418469
Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6–30.
doi: 10.1136/gutjnl-2016-312288
pubmed: 27707777
Lee A, Hong J, Chung H et al. Author Correction: Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia. Sci Rep 2020;10:18198.
doi: 10.1038/s41598-020-74316-1
pubmed: 33082421
pmcid: 7576199
Monzón H, Forné M, Esteve M et al. Helicobacter pylori infection as a cause of iron deficiency anaemia of unknown origin. World J Gastroenterol 2013;19:4166–4171.
doi: 10.3748/wjg.v19.i26.4166
pubmed: 23864779
pmcid: 3710418
Zhang J, Chen Z, Ma M et al. Soluble ST2 in coronary artery disease: clinical biomarkers and treatment guidance. Front Cardiovasc Med 2022;9:924461.
doi: 10.3389/fcvm.2022.924461
pubmed: 36225958
pmcid: 9548599
Boga S, Alkim H, Koksal AR et al. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity. J Investig Med 2016;64:1016–1024.
doi: 10.1136/jim-2016-000062
pubmed: 27001944
Hur M, Kim H, Kim HJ et al. Soluble ST2 has a prognostic role in patients with suspected sepsis. Ann Lab Med 2015;35:570–577.
doi: 10.3343/alm.2015.35.6.570
pubmed: 26354344
pmcid: 4579100
Iwahana H, Yanagisawa K, Ito-Kosaka A et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999;264:397–406.
doi: 10.1046/j.1432-1327.1999.00615.x
pubmed: 10491084
Homsak E, Gruson D. Soluble ST2: a complex and diverse role in several diseases. Clin Chim Acta 2020;507:75–87.
doi: 10.1016/j.cca.2020.04.011
pubmed: 32305537
Savarimuthu S, Goel P, Harky A. Soluble ST2: a valuable prognostic marker in heart failure. Heart Fail Rev 2022;27:2155–2164.
doi: 10.1007/s10741-022-10258-2
pubmed: 35759079
Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol 2015;115:3B-7B.
doi: 10.1016/j.amjcard.2015.01.034
pubmed: 25665766
De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis: role in health and disease. Cytokine Growth Factor Rev 2015;26:615–623.
doi: 10.1016/j.cytogfr.2015.07.017
pubmed: 26271893
Lu D-P, Zhou X-Y, Yao L-T et al. Serum soluble ST2 is associated with ER-positive breast cancer. BMC Cancer 2014;14:198.
doi: 10.1186/1471-2407-14-198
pubmed: 24636276
pmcid: 3995159
Bergis D, Kassis V, Radeke HH. High plasma sST2 levels in gastric cancer and their association with metastatic disease. Cancer Biomark 2016;16:117–125.
doi: 10.3233/CBM-150547
pubmed: 26835712
Kuo C-J, Chen C-Y, Lo H-R et al. Helicobacter pylori induces IL-33 production and recruits ST-2 to lipid rafts to exacerbate inflammation. Cells. 2019. https://doi.org/10.3390/cells8101290 .
doi: 10.3390/cells8101290
pubmed: 31817208
pmcid: 6952949
Wernly S, Wernly B, Semmler G et al. Non-alcoholic fatty liver disease is not independently associated with Helicobacter pylori in a Central European screening cohort. Minerva Med. 2022. https://doi.org/10.23736/S0026-4806.22.07928-9 .
doi: 10.23736/S0026-4806.22.07928-9
pubmed: 35384436
Wernly S, Semmler G, Völkerer A et al. Cardiovascular risk assessment by SCORE2 predicts risk for colorectal neoplasia and tumor-related mortality. J Pers Med. 2022. https://doi.org/10.3390/jpm12050848 .
doi: 10.3390/jpm12050848
pubmed: 35629269
pmcid: 9146398
Semmler G, Wernly S, Wernly B et al. Machine learning models cannot replace screening colonoscopy for the prediction of advanced colorectal adenoma. J Pers Med. 2021. https://doi.org/10.3390/jpm11100981 .
doi: 10.3390/jpm11100981
pubmed: 34945736
pmcid: 8709210
Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2:231–237.
doi: 10.1242/dmm.001180
pubmed: 19407331
pmcid: 2675814
Winter N, Nichols A. VIOPLOT: Stata module to produce violin plots with current graphics. Published Online First: 17 June 2012. https://EconPapers.repec.org/RePEc:boc:bocode:s456902 (Accessed 28 Feb 2023).
Gonciarz W, Krupa A, Moran AP et al. Interference of LPS H pylori with IL-33-driven regeneration of caviae porcellus primary gastric epithelial cells and fibroblasts. Cells. 2021. https://doi.org/10.3390/cells10061385 .
doi: 10.3390/cells10061385
pubmed: 34199843
pmcid: 8227243
Buzzelli JN, Chalinor HV, Pavlic DI et al. IL33 is a stomach alarmin that initiates a skewed Th2 response to injury and infection. Cell Mol Gastroenterol Hepatol 2015;1:203–21.e3.
doi: 10.1016/j.jcmgh.2014.12.003
pubmed: 28210674
pmcid: 5301136
Pfetsch V, Sanin V, Jaensch A et al. Increased plasma concentrations of soluble ST2 independently predict mortality but not cardiovascular events in stable coronary heart disease patients: 13-year follow-up of the KAROLA study. Cardiovasc Drugs Ther 2017;31:167–177.
doi: 10.1007/s10557-017-6718-1
pubmed: 28283847
Hammer F, Genser B, Dieplinger B et al. Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus. Clinical Kidney J. 2022;15:1915–1923. https://doi.org/10.1093/ckj/sfac142 .
doi: 10.1093/ckj/sfac142
Gürgöze MT, van Vark LC, Baart SJ et al. Multimarker analysis of serially measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, creatinine, and prognosis in acute heart failure. Circ Heart Fail 2023;16:e009526.
doi: 10.1161/CIRCHEARTFAILURE.122.009526
pubmed: 36408685
Shakerian L, Kolahdooz H, Garousi M et al. IL-33/ST2 axis in autoimmune disease. Cytokine 2022;158:156015.
doi: 10.1016/j.cyto.2022.156015
pubmed: 36041312
Song Y, Wei F, Liu Y et al. IL-33/ST2 activation is involved in Ro60-regulated photosensitivity in cutaneous lupus erythematosus. Mediators Inflamm 2022;2022:4955761.
doi: 10.1155/2022/4955761
pubmed: 35909659
pmcid: 9328989
Shi L-J, Liu C, Li J-H et al. Elevated levels of soluble ST2 were associated with rheumatoid arthritis disease activity and ameliorated inflammation in synovial fibroblasts. Chin Med J 2018;131:316–322.
doi: 10.4103/0366-6999.223847
pubmed: 29363647
pmcid: 5798053
Park M, Hur M, Kim H et al. Soluble ST2 as a useful biomarker for predicting clinical outcomes in hospitalized COVID-19 patients. Diagnostics (Basel). 2023. https://doi.org/10.3390/diagnostics13020259 .
doi: 10.3390/diagnostics13020259
pubmed: 37443569
pmcid: 9951688
Van Nynatten LR, Slessarev M, Martin CM et al. Novel plasma protein biomarkers from critically ill sepsis patients. Clin Proteomics 2022;19:50.
doi: 10.1186/s12014-022-09389-3
pubmed: 36572854
pmcid: 9792322
Søndergaard FT, Beske RP, Frydland M et al. Soluble ST2 in plasma is associated with post-procedural no-or-slow reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2023;12:48–52.
doi: 10.1093/ehjacc/zuac146
pubmed: 36355574
Pfetsch V, Sanin V, Jaensch A et al. Increased concentrations of soluble ST2 independently predict cardiac and total mortality but not non-fatal cardiovascular events in stable coronary heart disease patients. Atherosclerosis. 2017;263:e46–e47. https://doi.org/10.1016/j.atherosclerosis.2017.06.159 .
doi: 10.1016/j.atherosclerosis.2017.06.159
Urban MH, Stojkovic S, Demyanets S et al. Soluble ST2 and all-cause mortality in patients with chronic obstructive pulmonary disease—a 10-year cohort study. J Clin Med Res 2021;11:56.
Zeyda M, Wernly B, Demyanets S et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes 2013;37:658–665.
doi: 10.1038/ijo.2012.118
Easterbrook PJ, Berlin JA, Gopalan R et al. Publication bias in clinical research. Lancet 1991;337:867–872.
doi: 10.1016/0140-6736(91)90201-Y
pubmed: 1672966
Chan A-W, Krleza-Jerić K, Schmid I et al. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 2004;171:735–740.
doi: 10.1503/cmaj.1041086
pubmed: 15451835
pmcid: 517858
Sahni P, Aggarwal R. Reporting and Publishing Research in the Biomedical Sciences. Singapore: Springer; 2018.
doi: 10.1007/978-981-10-7062-4